ACP
UTHR icon

Acuta Capital Partners’s United Therapeutics UTHR Stock Holding History

Acuta Capital Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-25,000
Closed -$2.81M – 74
2018
Q1 		$2.81M Buy
+25,000
New +$3.18M 0.46% 32

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Acuta Capital Partners's UTHR Position: Q2 2026 in Review

Acuta Capital Partners held its United Therapeutics (UTHR) position steady in Q2 2026 at 2,224 shares worth $1.21M. The position accounts for 0.84% of the portfolio, ranked #21.

Acuta Capital Partners first reported a position in UTHR in Q3 2021 and has held it in 9 quarters since. The position peaked at $9.18M in Q4 2022. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Acuta Capital Partners held 2,224 shares of United Therapeutics worth $1.21M as of Q2 2026.
  • Acuta Capital Partners left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up 0.84% of Acuta Capital Partners's portfolio in Q2 2026, its #21 holding.
  • Acuta Capital Partners first reported a position in United Therapeutics in Q3 2021 and has held it in 9 quarters since.
  • Acuta Capital Partners's United Therapeutics position peaked at $9.18M in Q4 2022.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.